Integrated Advisors Network LLC Acquires Shares of 3,275 DexCom, Inc. (NASDAQ:DXCM)

Integrated Advisors Network LLC bought a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 3,275 shares of the medical device company's stock, valued at approximately $255,000.

A number of other institutional investors have also bought and sold shares of the business. Brighton Jones LLC lifted its stake in DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company's stock worth $1,290,000 after purchasing an additional 11,946 shares in the last quarter. Dynamic Advisor Solutions LLC lifted its stake in DexCom by 26.8% in the 4th quarter. Dynamic Advisor Solutions LLC now owns 3,902 shares of the medical device company's stock worth $303,000 after purchasing an additional 825 shares in the last quarter. Flagship Harbor Advisors LLC purchased a new stake in DexCom in the 4th quarter worth $454,000. Union Bancaire Privee UBP SA purchased a new stake in DexCom in the 4th quarter worth $225,000. Finally, Mount Yale Investment Advisors LLC purchased a new stake in DexCom in the 4th quarter worth $713,000. Hedge funds and other institutional investors own 97.75% of the company's stock.

Insider Transactions at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 32,498 shares of DexCom stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the sale, the chief executive officer now owns 372,029 shares of the company's stock, valued at approximately $26,183,401.02. The trade was a 8.03% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Jacob Steven Leach sold 14,076 shares of DexCom stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $990,668.88. Following the sale, the chief operating officer now directly owns 313,497 shares of the company's stock, valued at approximately $22,063,918.86. This represents a 4.30% decrease in their position. The disclosure for this sale can be found here. Insiders sold 83,110 shares of company stock valued at $6,103,505 in the last quarter. 0.32% of the stock is currently owned by corporate insiders.

DexCom Stock Up 1.3%

Shares of DexCom stock traded up $1.10 during trading on Friday, reaching $85.96. The company's stock had a trading volume of 4,257,051 shares, compared to its average volume of 4,370,189. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The company has a market cap of $33.71 billion, a price-to-earnings ratio of 60.11, a P/E/G ratio of 2.30 and a beta of 1.43. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $121.47. The company has a 50-day simple moving average of $74.67 and a two-hundred day simple moving average of $78.65.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The business had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a return on equity of 30.14% and a net margin of 14.29%. The firm's revenue for the quarter was up 12.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.32 EPS. As a group, equities analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have commented on DXCM shares. Piper Sandler decreased their price target on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a research note on Friday, May 2nd. The Goldman Sachs Group assumed coverage on shares of DexCom in a report on Friday. They issued a "buy" rating and a $104.00 target price on the stock. Canaccord Genuity Group boosted their target price on shares of DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Finally, Robert W. Baird reduced their target price on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Five equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $98.32.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.